Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis.
Chao LiJie YuCarinna HockhamVlado PerkovicBrendon L NeuenSunil V BadveLauren HoustonVivian Y J LeeJennifer Y BarracloughRobert A FletcherKenneth W MahaffeyHiddo J Lambers HeerspinkChristopher P CannonBruce C NealClare ArnottPublished in: Diabetes, obesity & metabolism (2022)
Overall, a significant effect of canagliflozin on the incidence of AF/AFL events could not be shown, however, a possible reduction in AF/AFL events in those with no prior history requires further investigation. Meta-analysis suggests SGLT2 inhibition reduces AF/AFL incidence.